Log In
BCIQ
Print this Print this
 

NITD304

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionInhibitor of mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)
Molecular Target Mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationTuberculosis
Indication DetailsTreat tuberculosis (TB) infection
Regulatory Designation
PartnerGlobal Alliance for TB Drug Development

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/20/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today